NCT01711983View on ClinicalTrials.gov

Safety and Efficacy of the GORE® Septal Occluder to Treat Ostium Secundum Atrial Septal Defects

NACompletedINTERVENTIONAL
Enrollment

400

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

November 26, 2018

Study Completion Date

November 26, 2018

Conditions
Septal Defect, Atrial
Interventions
DEVICE

GORE® CARDIOFORM Septal Occluder

Percutaneous Atrial Septal Defect Closure

Trial Locations (1)

22908

University of Virginia, Children's Hospital Heart Center, Charlottesville

All Listed Sponsors
lead

W.L.Gore & Associates

INDUSTRY

NCT01711983 - Safety and Efficacy of the GORE® Septal Occluder to Treat Ostium Secundum Atrial Septal Defects | Biotech Hunter | Biotech Hunter